Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease

Published:2016-02 Issue:2 Volume:48 Page:138-143
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Guiotto Cristina^ORCID,Daperno Marco,Frigerio Francesco^ORCID,Vizzini Margherita,Cerruti Roberta,Ercole Elena,Cosimato Maurizio,Lavagna Alessandro,Germano Laura,Migliardi Marco,Rocca Rodolfo

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference37 articles.

1. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management;Dignass;Journal of Crohn's and Colitis,2012

2. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management;Dignass;Journal of Crohn's and Colitis,2010

3. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease;Orlando;Digestive and Liver Disease,2011

4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease;Baert;New England Journal of Medicine,2003

5. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial;Farrell;Gastroenterology,2003

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay;Therapeutic Drug Monitoring;2023-02-15

2. Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?;Intestinal Research;2021-10-31

3. Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity;Annals of Laboratory Medicine;2020-03-01

4. Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab;Crohn's & Colitis 360;2019-08-19

5. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases;Clinical Gastroenterology and Hepatology;2019-08